8RK Stock Overview
Develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Labiana Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.60 |
| 52 Week High | €2.60 |
| 52 Week Low | €0.93 |
| Beta | -0.44 |
| 11 Month Change | 27.45% |
| 3 Month Change | 79.31% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8RK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.6% | -4.8% | 0.8% |
| 1Y | n/a | -19.4% | 2.0% |
Return vs Industry: Insufficient data to determine how 8RK performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 8RK performed against the German Market.
Price Volatility
| 8RK volatility | |
|---|---|
| 8RK Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8RK's share price has been volatile over the past 3 months.
Volatility Over Time: 8RK's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 433 | Manuel Ortega | www.labiana.com |
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized, and biological formats; and Fosfomycin trometamol under the Fosfomicina Labiana brand name.
Labiana Health, S.A. Fundamentals Summary
| 8RK fundamental statistics | |
|---|---|
| Market cap | €19.07m |
| Earnings (TTM) | -€4.42m |
| Revenue (TTM) | €59.70m |
0.3x
P/S Ratio-4.3x
P/E RatioIs 8RK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8RK income statement (TTM) | |
|---|---|
| Revenue | €59.70m |
| Cost of Revenue | €27.03m |
| Gross Profit | €32.67m |
| Other Expenses | €37.09m |
| Earnings | -€4.42m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 54.73% |
| Net Profit Margin | -7.41% |
| Debt/Equity Ratio | 1,180.3% |
How did 8RK perform over the long term?
See historical performance and comparison